Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

2.

Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)

Mulder JW, Cooper DA, Mathiesen L, Sandström E, Clumeck N, Gatell JM, French M, Donovan B, Gray F, Yeo JM, et al.

AIDS. 1994 Mar;8(3):313-21. Erratum in: AIDS 1994 Jun;8(6):following 859.

PMID:
7913326
3.

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.

Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS, et al.

N Engl J Med. 1995 Aug 17;333(7):401-7.

4.

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, et al.

Ann Intern Med. 1990 May 15;112(10):727-37.

PMID:
1970466
5.

Impact of treatment changes on the interpretation of the Concorde trial.

White IR, Walker S, Babiker AG, Darbyshire JH.

AIDS. 1997 Jul;11(8):999-1006.

PMID:
9223734
6.
7.

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J, et al.

N Engl J Med. 1993 Jul 29;329(5):297-303.

9.

Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. The Italian Zidovudine Evaluation Group.

Vella S, Giuliano M, Dally LG, Agresti MG, Tomino C, Floridia M, Chiesi A, Fragola V, Moroni M, Piazza M, et al.

J Acquir Immune Defic Syndr. 1994 Jan;7(1):31-8.

PMID:
7903380
10.

The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.

Cooper DA, Pehrson PO, Pedersen C, Moroni M, Oksenhendler E, Rozenbaum W, Clumeck N, Faber V, Stille W, Hirschel B, et al.

AIDS. 1993 Feb;7(2):197-207.

PMID:
8096703
11.

Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?

Easterbrook PJ, Goodall RL, Babiker AG, Yu LM, Smith D, Cooper DA, Gazzard BG.

J Antimicrob Chemother. 1999 Mar;43(3):379-88.

13.

The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.

Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT, et al.

JAMA. 1994 Aug 10;272(6):437-42.

PMID:
7913730
14.

Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.

Mannucci PM, Gringeri A, Savidge G, Gatenby P, Laurian Y, Pabinger-Fasching I, Martinez-Vazquez JM, Hessey EW, Steel HM.

Br J Haematol. 1994 Jan;86(1):174-9.

PMID:
7912097
15.

A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, et al.

N Engl J Med. 1992 Feb 13;326(7):437-43.

16.

Markers of HIV infection in the Concorde trial. Concorde Co-ordinating Committee.

Walker AS, Peto TE, Babiker AG, Darbyshire JH.

QJM. 1998 Jun;91(6):423-38.

17.

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G, et al.

N Engl J Med. 1992 Aug 27;327(9):581-7.

18.

Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.

Goldstein G, Conant MA, Beall G, Grossman HA, Galpin JE, Blick G, Calabrese LH, Hirsch RL, Fisher A, Stampone P, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):279-88.

PMID:
7859140
19.

Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.

Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, Josipovic D, Liberty A, Lazarus E, Innes S, van Rensburg AJ, Pelser W, Truter H, Madhi SA, Handelsman E, Jean-Philippe P, McIntyre JA, Gibb DM, Babiker AG; CHER Study Team.

Lancet. 2013 Nov 9;382(9904):1555-63. doi: 10.1016/S0140-6736(13)61409-9.

20.

Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.

Merigan TC, Amato DA, Balsley J, Power M, Price WA, Benoit S, Perez-Michael A, Brownstein A, Kramer AS, Brettler D, et al.

Blood. 1991 Aug 15;78(4):900-6.

Items per page

Supplemental Content

Write to the Help Desk